Cynata Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Key Metrics
PE ratio
-
PB ratio
13.46
Dividend yield
-
Beta
0.99
Market cap
$83.11M
Enterprise value
$78.06M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.cynata.com |
| Mailing address | 100 Cubitt Street Level 3 Cremorne VIC 3121 Australia |
| Phone / Fax | 61 3 7067 6940 / 61 3 7067 6940 |
Dividends
More: Cynata Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Cynata Therapeutics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CYP dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Cynata Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Kilian Kelly Ph.D. | MD, CEO & Director | ||
| Dr. Jolanta Airey | Chief Medical Officer | ||
| Dr. Mathias Kroll | Chief Business Officer | ||
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | 62 |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
7014.20%
Return on assets
-77.08%
Return on equity
-142.29%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Cynata Therapeutics is 83.11M and its enterprise value is 78.06M. The enterprise value to revenue ratio of CYP is 41.41. The enterprise value to EBITDA ratio of CYP is -8.37.
The CYP's stocks Beta value is 0.99 making it 1% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Cynata Therapeutics (CYP)
Cynata Therapeutics (ASX:CYP) Frequently Asked Questions
1. What is Cynata Therapeutics's Stock Symbol?
Cynata Therapeutics trades on ASX under the ticker symbol "CYP".
2. What is Cynata Therapeutics's stock price today?
One share of CYP stock can currently be purchased for approximately $0.35.
3. How can I contact Cynata Therapeutics?
Cynata Therapeutics's mailing address is 100 Cubitt Street Level 3 Cremorne VIC 3121 Australia. The company can be reached via phone at 61 3 7067 6940.
4. What is Cynata Therapeutics's official website?
The official website of Cynata Therapeutics is https://www.cynata.com.